Arrowhead Research

Arrowhead raises additional capital from institutional shareholders

Published in Lab Business Week, September 24th, 2006

Arrowhead Research Corp., (ARWR) a nanotechnology company, has closed the sale of 204,918 shares of restricted common stock to Knott Partners, LP and Potomac Capital Partners, LP and certain of their affiliates.

A portion of the proceeds of the sale was used to increase Arrowhead's ownership position in its majority-owned subsidiary, Calando Pharmaceuticals.

Under the terms of the agreement, Knott Partners and Potomac Capital purchased 102,250 and 102,668 shares, respectively of restricted common stock at $4.88 per share which represents the 10-day trailing average price from August 4, the date Arrowhead's board approved the transaction.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2006-09-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry